GlassScriptPhysician profile
Jaime Porter
NPI 1639619299
$3,748.42
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $1,042 · 2023: $967 · 2024: $941 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $856.28 | 2021-2024 | Micra, Aurora Ev-Icd Mri Surescan, Selectsecure |
| Pfizer INC. | $743.89 | 2021-2025 | |
| Abbott Laboratories | $244.32 | 2023-2025 | Jeti, Jeti All In One Non-Sterile Kit, Perclose Prostyle |
| E.R. Squibb & Sons, L.L.C. | $240.41 | 2021-2024 | Camzyos |
| Alnylam Pharmaceuticals INC. | $235.80 | 2022-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.39 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $165.88 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $154.28 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $139.43 | 2022-2024 | |
| Amgen INC. | $133.59 | 2021-2024 | Repatha |
| Daiichi Sankyo INC. | $131.32 | 2022-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $93.93 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.77 | 2022-2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $53.21 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $41.48 | 2022-2024 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $41.31 | 2024 | Inspire |
| Altathera Pharmaceuticals LLC | $41.07 | 2023 | Sotalol Hydrochloride |
| Philips North America LLC | $37.67 | 2025 | Ecc Solutions, Mcot |
| Cardiovascular Systems INC. | $31.02 | 2022-2023 | Diamondback Coronary |
| Esperion Therapeutics, INC. | $22.25 | 2021 | |
| Scpharmaceuticals INC. | $19.31 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.08 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.